Baudax Bio Inc. (BXRX)

BX2000 Phase I First Cohort Dosed


Gregory AurandMedia Inquiries
Senior Healthcare Services & Medical Devices Analyst
June 2, 2022
Report ID: 24924
Get Report
Refer to the full report for the price target, fundamental analysis, and rating.

Equity Research provided by Noble Capital Markets is available at no cost to Registered users of Channelchek.

Already Registered? Click the ‘Get Report’ button to login and view the research report.

Not a Member? Click ‘Join’ or ‘Get Report’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.


Baudax Bio Inc.
Baudax Bio Inc.
Healthcare
Biotechnology
Ticker
BXRX
Current Price
$3.28 5.47%
Market Cap
$1.8M
Price Target
Refer to Report
Volume
448.1K
52wk Range
$1.55 - $306.46

Comments

0
No comments yet...
Related Research Reports
1/25/2023

Baudax Bio Announces Positive Interim Analysis Of BX1000 Phase II Trial
Baudax Bio Announces Positive Interim Analysis Of BX1000 Phase II Trial (BXRX)
1/3/2023

Baudax Bio Discontinuing ANJESO Sales; Reducing Rating To Market Perform
Baudax Bio Discontinuing ANJESO Sales; Reducing Rating To Market Perform (BXRX)
12/7/2022

Closing of $5 million Public Offering is Announced
Closing of $5 million Public Offering is Announced (BXRX)
12/1/2022

Curing the Deficiency: Reverse Stock Split
Curing the Deficiency: Reverse Stock Split (BXRX)

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
© 2018-2023 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.